You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca and Merck & Co have announced that the European Medicines Agency has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). “There is no cure for NF1, a life-long and devastating condition, and current treatment choicAlready a subscriber Login You have…
Orion is planning to change and refocus the strategy of its R&D function and in the future focus would be on cancer and pain. Orion will initiate negotiations concerning in total 430 salaried employees and senior salaried employees in Finland in Espoo, Turku and Kuopio in the research areas iAlready…
Moberg Pharma announces that the company has decided to issue a five-year senior unsecured bond loan in the amount of SEK 300 million with maturity on January 29th, 2021. The bond loan will give a floating rate coupon of Stibor 3m + 6.00% and have a total framework amount of SEK…
Swedish Orphan Biovitrum announces that the Saudi Food & Drug Authority in the Kingdom of Saudi Arabia has approved Alprolix (eftrenonacog alfa), for the treatment of haemophilia B. Alprolix is the first extended half-life and recombinant factor IX Fc fusion protein therapy approved for theAlready a subscriber Login You have read all…
